Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime ...

Please provide your email address to receive an email when new articles are posted on . The SCAI shock classification system may provide mortality risk stratification of patients at risk for or who ...

SEISMiC Extension Study results are anticipated in mid-2024 and expected to provide dose optimization for Phase 3 The Company is also progressing a parallel SCAI Stage C Phase 2 study with istaroxime ...

Numerous knowledge gaps exist regarding the care of female patients with cardiogenic shock, often because they have been consistently underrepresented in clinical trials, according to a new consensus ...

First released in 2019, the Society for Cardiovascular Angiography and Interventions (SCAI) cardiogenic shock categories have gotten a rethink, one that adds nuance to aid decision-making and ...

LAS VEGAS — In this video exclusive, Cardiology Today Editorial Board Member Timothy Henry, MD, FACC, MSCAI, Lindner Family Distinguished Chair in Clinical Research and medical director of The Carl ...

The Society for Cardiovascular Angiography and Interventions (SCAI) has released a new consensus statement on the classification of cardiogenic shock (CS). The statement, authored by a ...

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, will feature the most recent Impella research and technological advances ...

The Society for Cardiovascular Angiography and Interventions (SCAI) has refined its cardiogenic shock (CS) classification system based on the literature and clinician feedback from real-world ...